secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001437749-25-011926
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience
----------------------------------------------------------------------------

- On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.
- Contract covered Phase 2b clinical trial of GEO-CM04S1 COVID-19 vaccine; terminated for convenience to the government.
- No financial details of termination or potential wind-down costs were disclosed in the filing.
- GeoVax common stock (GOVX) and warrants (GOVXW) trade on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774925011926/0001437749-25-011926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774925011926/govx20250414_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-011926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer